drug price – Page 2

Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing

3 months ago talkbio0Tagged drug price, Impact food supplement, Pharma import taxes, pharmaceutical manufacturing, Pharmaceutical stocks, pharmaceutical tariffs, Policy, Relations, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.-China, United States

Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks

Drug pricing watchdog ICER offers ways to increase obesity drug access

3 months ago talkbio0Tagged Access, drug price, ICER, Obesity, Policy, Wegovy

ICER, Obesity, Access, Wegovy, Policy, drug price

Drug Pricing and the Uncertain Future of the IRA Under Trump

4 months ago talkbio0Tagged Changing, drug price, IRA, Mediation, Medicare, Prices, repeal, Transplant Registry Unified Management Program, Uncertainty

IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices

Medicare Selects Ozempic, Wegovy for Price Negotiations: A Step Towards Lowering Prescription Drug Costs

6 months ago talkbio0Tagged drug price, Health care facility, Inflation, Mediation, Medicare, Prescription procedure, seniors, Wegovy

Medicare, drug price negotiations, Ozempic, Wegovy, Inflation Reduction Act, prescription drug costs, seniors, healthcare.

Understanding the Second Round of Medicare Drug Price Negotiations: What Trump’s CMS Can and Can’t Change

6 months ago talkbio0Tagged Administration occupational activities, CMS, drug price, Inflation, Medicare, Myasthenic Syndromes, Congenital, negotiation, Prices, Transplant Registry Unified Management Program

Medicare drug price negotiation, Trump administration, CMS, Inflation Reduction Act, drug prices, negotiation process

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

7 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

ICER Report Highlights $815 Million in Unjustified Drug Price Increases in 2023

7 months ago talkbio0Tagged 2023, CREM gene, drug price, Health care facility, pharmaceutical costs, Report (document)

ICER report, unsupported drug price hikes, 2023, pharmaceutical costs, healthcare spending

Supreme Court Declines to Review PhRMA’s Challenge to Arkansas’ 340B Contract Pharmacy Law

7 months ago talkbio0Tagged 1103, Arkansas, Contract agreement, court, drug price, federal, Pharmacy facility, PhRMA, Programs - Publication Format, Supreme

340B Program, Arkansas Act 1103, PhRMA, Supreme Court, Contract Pharmacies, Drug Pricing, Federal Preemption

Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts

7 months ago talkbio0Tagged Acquisitions, Drug Industry, drug price, Healthcare M&A, Inflation, Ira (eukaryote), Mediation, Medicare, mergers, Negotiation Program, Prices, trends qualifier

Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024

Lawmakers Scrutinize Pharma’s Telehealth Marketing Tactics Amid Concerns Over Patent Abuse and High Drug Prices

8 months ago talkbio0Tagged Drug Industry, drug price, Lawmaker scrutiny, Patent Abuse, Pharma telehealth programs, Practice Experience

Pharma telehealth programs, Patent abuse, High drug prices, Lawmaker scrutiny, Pharmaceutical industry practices